Wednesday, April 24, 2024 11:58:27 AM
Glad you are not concerned but the vast majority of investors or potential investors may not even realize there is a boat load being given out at dirt price, nor do they even understand what that means.
Why are those placement shares @ $0.0003? That is a 40x discount which is crazy.
Investors should note shares offered at $0.0003 is a DOWN round since previous shares 'look like' they were offered 3-5x higher.
For those that don't know: A “down round” is a financing in which a company sells shares of its capital stock at a price per share that is less than the price per share it sold shares for in an earlier financing
My experience with private placement stock that is restricted and unregistered, may be restricted from 6 to 12 months before you can removed the legend and sell them.
It's 3 weeks past the 1 year date on a lot of them with even more eligible coming.
https://www.otcmarkets.com/otcapi/company/financial-report/393762/content
5 Conditions for Resale of Rule 144 Securities
Five conditions must be met for restricted, unregistered, and control securities to be sold or resold.
1. The prescribed holding period must be met. For a public company, the holding period is six months, beginning on the date a holder purchased and paid for the securities. For a company that does not have to make filings with the SEC, the holding period is one year. The holding period requirements apply primarily to restricted securities, while the resale of control securities is subject to the other requirements under Rule 144.
2. There must be adequate current public information available to investors about a company, including historical financial statements, information about officers and directors, and a business description.
3. If a selling party is an affiliate of a company, he cannot resell more than 1% of the total outstanding shares during any three-month period. If a company's stock is listed on a stock exchange, only the greater of 1% of total outstanding shares, or the average of the previous four-week trading volume can be sold. For over-the-counter stocks, only the 1% rule applies.
4. All of the normal trading conditions that apply to any trade must be met. In particular, brokers cannot solicit buy orders, and they are not allowed to receive commissions in excess of their normal rates.
5. An affiliated seller must file a proposed sale notice if the sale value exceeds $50,000 during any three-month period, or if more than 5,000 shares are proposed for sale.
https://www.google.com/search?q=6+to+12+months+before+you+can+removed+the+legend+and+sell+them&rlz=1C1SQJL_enUS886US886&sourceid=chrome&ie=UTF-8
Recent MRES News
- M2Bio Sciences Appoints Adrian J. Maizey, Accomplished CEO and Financial Expert, to Advisory Board • InvestorsHub NewsWire • 07/19/2023 01:18:56 PM
- M2Bio Sciences Unveils an Exciting Line of Purple, White, and Green Teas from Kenya, Offering Extraordinary Health and Medicinal Benefits • InvestorsHub NewsWire • 07/14/2023 12:52:00 PM
- M2Bio Sciences Unveils Explainer Video Showcasing Groundbreaking NFTs and Altcoins for Drug Discovery, Revolutionizing Investment Access • InvestorsHub NewsWire • 07/06/2023 01:38:23 PM
- Institute of Biomedical Research Announces Application for Name Change and New Ticker Symbol in Anticipation of Future M&A Activities and Senior Listing • InvestorsHub NewsWire • 07/05/2023 02:04:17 PM
- M2Bio Sciences Enters into Letter of Intent to Acquire Crypto Exchange JDAX • InvestorsHub NewsWire • 06/26/2023 12:45:19 PM
- M2Bio Sciences Establishes Research Chair at The University of Pretoria for Phytomedicines • InvestorsHub NewsWire • 06/16/2023 12:30:00 PM
- M2Enviro Expands R&D Efforts to Explore Diverse Classes of Mycelium Composite Materials for Commercialization • InvestorsHub NewsWire • 06/14/2023 12:00:00 PM
- Institute of Biomedical Research unveils artificial intelligence (AI) powered initiatives within its CBD product range, psilocybin research, and cardiometabolic health solutions • InvestorsHub NewsWire • 06/07/2023 02:06:41 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM